New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience ...

Aspire Biopharma (ASBP) announced the filing of a new provisional patent application with the United States Patent and ...

News of the expanded indication comes during a showdown between the marketer/manufacturer of the drug, Bristol-Myers Squibb (BMS)/Sanofi-Aventis, and Canadian drug company Apotex, which started ...

PARIS/LONDON (Reuters) - French drugmaker Sanofi-Aventis is preparing to sell its own generic version of the blockbuster heart medicine Plavix in France, a company spokesman said on Monday. Plavix, ...

Sanofi-Aventis and Bristol-Myers Squibb have cut a deal with a generic company that could keep a copycat version of their multibillion drug Plavix off the market until 2011. Sanofi-Aventis and Bristol ...

LONDON (Reuters) - Sanofi-Aventis and Bristol-Myers Squibb , which are just recovering from defeating generic competition to their top-selling Plavix drug in the United States, now face a similar ...

TRENTON, N.J. (AP) The first generic competition to Bristol-Myers Squibb Co.'s top-selling drug, blockbuster blood thinner Plavix, has slashed sales as expected, dragging down the drugmaker's ...

A former senior vice-president at Bristol-Myers Squibb has been charged by the US Department of Justice with lying to federal authorities over a deal struck with rival generics maker Apotex. According ...

Shares in Bristol-Myers Squibb continued to decline on Friday as expectation grew that a generic form of its big-selling antithrombotic Plavix could be on the market in the USA later this year. Shares ...

Generic drug maker Apotex Inc. caught the market by surprise yesterday, launching a cheaper copy of the best-selling, blood thinner Plavix in the United States ahead of a likely patent infringement ...